SCIENTIFIC PUBLICATIONS AND NEWS

Selected publications reflecting our scientific approach on the EGF-platform and the xB3-platform are highlighted below

EGF-Platform

Linnerbauer M, Lößlein L, Vandrey O, Peter A, Han Y, Tsaktanis T, Wogram E, Needhamsen M, Kular L, Nagel L, Zissler J, Andert M, Meszaros L, Hanspach J, Zuber F, Naumann UJ, Diebold M, Wheeler MA, Beyer T, Nirschl L, Cirac A, Laun FB, Günther C, Winkler J, Bäuerle T, Jagodic M, Hemmer B, Prinz M, Quintana FJ, Rothhammer V.
The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology
Nat Immunol. 2024 March

Nicoletti F, Mazzon E, Fagone P, Mangano K, Mammana S, Cavalli E, Basile MS, Bramanti P, Scalabrino G, Lang AB, Curtin F.
Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF
J Neuroimmunol. 2019 July

Scalabrino G.
Epidermal Growth Factor in the CNS: A Beguiling Journey from Integrated Cell Biology to Multiple Sclerosis. An Extensive Translational Overview.
Cell Mol Neurobiol. 2020 Nov

Wei J and Besner GE.
M1 to M2 macrophage polarization in heparin-binding epidermal growth factor-like growth factor therapy for necrotizing enterocolitis
J. Surg Res 2015 July

Knapp PE and Adams MH.
Epidermal growth factor promotes oligodendrocyte process formation and regrowth after injury
Exp Cell Res 2004 June

Scalabrino G. Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E.
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis.
Brain Res 2010 May

Sullivan PB, Lewindon PJ, Cheng C, Lenehan PF, Kuo B-S, Haskins JR, Goodlad RA, Wright NA, de la Iglesia FA.
Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis
J. Pediatr Surg 2007 March

Scalabrino G.
The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency.
Progr Neurobiol 2009 April

xB3-platform

Thom G, Tian MM, Hatcher JP, Rodrigo N, Burrell M, Gurrell I, Vitalis TZ, Abraham T, Jefferies WA, Webster CI and Gabathuler R
A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model
J Cereb Blood Flow Metab 2019 Oct

Terstappen GC, Meyer AH, Bell RD and Zhang W
Strategies for delivering therapeutics across the blood–brain barrier
Nature Review Drug Discov 2021 May

Eyford BA, Singh CSB, Abraham T, Munro L, Choi KB, Hill T, Hildebrandt R, Welch I, Vitalis TZ, Gabathuler R, Gordon JA, Adomat H, Guns EST, Lu CJ, Pfeifer CG, Tian MM, Jefferies WA.
A Nanomule Peptide Carrier Delivers siRNA Across the Intact Blood-Brain Barrier to Attenuate Ischemic Stroke.
Front Mol Biosci. 2021 March

Nounou MI, Adkins CE, Rubinchik E, Terrell-Hall TB, Afroz M, Vitalis T, Gabathuler R, Tian MM, Lockman PR
Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2þ breast cancer tumors in the brain: an in-vivo study.
Pharm Res 2016 Dec

Strickland DK and Muratoglu SC
LRP in Endothelial Cells: A Little Goes a Long Way
Arterioscler Thromb Vasc Biol 2016 Feb